The efficacy and safety of testosterone undecanoate (nebido®) in testosterone deficiency syndrome in Korean: A multicenter prospective study

Journal of Sexual Medicine

Volumn 7, Issue 6, 2010, Pages 2253-2260

  Moon, Du Geon ^a   Park, Min Gu ^a   Lee, Sung Won ^b   Park, Kwangsung ^c   Park, Jong Kwan ^d   Kim, Sae Woong ^e   Park, Nam Cheol ^f   Ahn, Tai Young ^g   Paick, Jae Seung ^h   Seo, Ju Tae ⁱ   Yang, Dae Yul ^j   Lee, June Young ^a   Kim, Je Jong ^a  

^a Korea University College of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Chonbuk National University   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Pusan National University School of Medicine   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

^h Seoul National University   (South Korea)

ⁱ Catholic Kwandong University   (South Korea)

^j Hallym University   (South Korea)

more..

Author keywords

Hypogonadism; Korea; Testosterone Deficiency Syndrome; Testosterone Undecanoate

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN; LIPID; LONG ACTING DRUG; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE UNDECANOATE; VARDENAFIL;

ACNE; ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; BODY MASS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; GYNECOMASTIA; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PENIS ERECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SOUTH KOREA; TESTOSTERONE BLOOD LEVEL;

EID: 77953918921     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01765.x     Document Type: Article

References (29)

1. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009, 21:1-8.
2. Morales A, Schulman C, Tostain J, Wu C. Testosterone deficiency syndrome (TDS) needs to be named appropriately-the importance of accurate terminology. Eur Urol 2006, 50:407-9.
3. Travison T, Morley J, Araujo A, O'donnell A, McKinlay J. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006, 91:2509-13.
4. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol (Oxf) 2005, 63:381-94.
5. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: Basic rationale and clinical evidences. Eur Urol 2006, 50:940-7.
6. Lotti F, Corona G, Mancini M, Biagini C, Colpi GM, Innocenti SD, Filimberti E, Gacci M, Krausz C, Forza A, Forti G, Mannucci E, Maggi M. The Relationship of Testosterone to Prostate-Specific Antigen in Men with Sexual Dysfunction. J Sex Med 2009, Nov 13. Epub ahead of pr
7. Nieschlag E. Testosterone treatment comes of age: New options for hypogonadal men. Clin Endocrinol (Oxf) 2006, 65:275-81.
8. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006, 91:1995-2010.
9. Seftel A. Testosterone replacement therapy for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2007, 19:2-24.
10. Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Shabsigh R, Swerdloff RS, Wang C. Long acting testosterone undecanoate therapy in men with hypogonadism: Results of a pharmacokinetic clinical study. J Urol 2008, 180:2307-13.
11. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhovel F. Intramuscular testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004, 89:5429-34.
12. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 1998, 19:761-8.
13. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study. J Androl 2002, 23:419-25.
14. Chung T, Lee T, Chung S, Lee M, Kim Y, Ahn T. The Korean Version of the International Index of Erectile Function(IIEF): Reliability and Validation Study Korean. J Urol 1999, 40:1334-43.
15. Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E, Moore C, Saad F, Potthoff P, Thai M. The Aging Males' Symptoms (AMS) scale: Review of its methodological characteristics. Health Qual Life Outcomes 2003, 1:77.
16. Wang L, Shi D, Lu S, Fang R. The therapeutic effect of domestically produced testosterone undecanoate in Klinefelter syndrome. New Drug Market 1991, 8:28-323.
17. Partsch C, Weinbauer G, Fang R, Nieschlag E. Injectable testosterone undecanoate has more favourable pharmaco-kinetics and pharmacodynamics than testosterone enanthate. Eur J Endocrinol 1995, 132:514-9.
18. Behre H, Abshagen K, Oettel M, Huebler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies. Eur J Endocrinol 1999, 140:414-9.
19. Nieschlag E, Büchter D, von Eckardsterin S, Abshagen K, Simoni M, Behre H. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999, 51:757-63.
20. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study. J Androl 2002, 23:419-25.
21. Morales A, Nieschlag E, Schubert M, Yassin AA, Zitzmann M, Oettel M. Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9-12 February 2006, Salzburg, Austria. Aging Male 2006, 9:221-7.
22. O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: A double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 2004, 89:2837-45.
23. Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: A critical appraisal. Clin Interv Aging 2007, 2:577-90.
24. Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L, Nieschlag E. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl 2007, 9:291-7.
25. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: A series of case reports. J Sex Med 2006, 3:727-35.
26. Gooren L, Saad F. Recent insight into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006, 8:3-9.
27. Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J Urol 2006, 24:639-44.
28. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007, 4:497-501.
29. O'Caroll R, Bancroft J. Testosterone therapy for low sexual interest and erectile dysfunction in men: A controlled study. Br J Psychiatry 1984, 145:146-51.